FMP
Liminal BioSciences Inc.
LMNL
NASDAQ
Inactive Equity
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
8.5 USD
0.01 (0.118%)
About
ceo
Mr. Bruce Pritchard BA, CA, FIOD
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
CIK
0001351172
ISIN
CA53272L1031
CUSIP
53272L103
Address
440 Armand-Frappier Boulevard
Phone
14507810115
Country
CA
Employee
251
IPO Date
Dec 18, 2009
Key Executives
Name
Title
Pay
Year Born
Dr. Christopher L. Penney
Chief Scientific Officer of Therapeutics...
0
N/A
Dr. Robert G. Rohwer
Member of Scientific Advisory Committee ...
0
N/A
Ms. N. Nicole Rusaw C.A., CPA
Chief Financial Officer
0
1974
Dr. John Bienenstock CM, FRCP, FRPC, FRSC, M.D.(Hon)
Member of Advisory Committee - Therapeut...
0
1937
Ms. N. Nicole Rusaw C.A., C.P.A.
Chief Financial Officer
0
1974
Mr. Bruce Pritchard BA, CA, FIOD
Chief Executive Officer
698.94k
1974
Mr. Patrick Sartore
Pres
613.82k
1975
Dr. Gary J. Bridger Ph.D.
Interim Chief Scientific Officer & Non-I...
264.69k
1963
Ms. Marie Iskra L.L.B.
Corporation Sec. & Gen. Counsel
435.82k
1977
Ms. N. Nicole Rusaw C.A., C.P.A., CA, CPA, HBACC
Chief Financial Officer
0
1973
Shrinal Inamdar
Mang. of Investor Relations & Communicat...
0
N/A
Dr. Steven J. Burton
Pres of Prometic Bioseparations Ltd
0
N/A
As of December 31, 2024, the total employee count stands at 251, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
